ModernVivo
ModernVivo provides AI-powered literature review and study design tools specifically for in vivo research. Their platform helps scientists accelerate study design, optimize resource efficiency, and improve translational success by automating data-driven literature reviews. The core offering, ModernVivo Atlas, analyzes thousands of papers to extract detailed in vivo study parameters, moving beyond keyword searches to provide precision. They also offer GeneScreen, a tool to identify the best genetic models for research. Their solution targets pharmaceutical companies, contract research organizations (CROs), academic labs, and IACUC committees, aiming to reduce costs, minimize timelines, and improve the quality of preclinical research. The business model appears to be SaaS, with a focus on providing actionable insights and streamlining complex research workflows.
ModernVivo
ModernVivo provides AI-powered literature review and study design tools specifically for in vivo research. Their platform helps scientists accelerate study design, optimize resource efficiency, and improve translational success by automating data-driven literature reviews. The core offering, ModernVivo Atlas, analyzes thousands of papers to extract detailed in vivo study parameters, moving beyond keyword searches to provide precision. They also offer GeneScreen, a tool to identify the best genetic models for research. Their solution targets pharmaceutical companies, contract research organizations (CROs), academic labs, and IACUC committees, aiming to reduce costs, minimize timelines, and improve the quality of preclinical research. The business model appears to be SaaS, with a focus on providing actionable insights and streamlining complex research workflows.
TL;DR
What: AI-powered literature review and study-design tools for in vivo preclinical research
Key products: ModernVivo Atlas (paper-scale extraction of in vivo study parameters); GeneScreen (genetic model selection)
Customers: Pharmaceutical companies, contract research organizations (CROs), academic labs, IACUC committees
Company facts: Founded 2023; industry: Data and Analytics; reported ~9 employees
Funding: Pre-seed stage; investors include Debiopharm Innovation Fund, University of Michigan, Desai Accelerator; Dealroom lists a $15k convertible (Aug 2023)
Company Overview
Problem Domain
Preclinical in vivo study design and literature review for biomedical research.
Founded
2023
Industry
Data and Analytics
Tech Stack
Funding Track Record
15000 USD
Dealroom lists an Aug 2023 convertible entry for $15.0k with Desai Accelerator.
Crunchbase lists a Pre-Seed round with Debiopharm Innovation Fund as lead investor and a last funding date of 2025-03-25.
Investor Signal
“Backed by early-stage investors including Debiopharm Innovation Fund, University of Michigan and Desai Accelerator; participation noted with Merck Digital Sciences Studio”